Terapia com células T CAR em República da Coreia — receba 3 correspondências de clínicas personalizadas

Qualified centers in South Korea must receive Ministry of Food and Drug Safety approval to administer CAR T-cell therapy. Primary authorized facilities include Samsung Medical Center, Seoul National University Hospital, and Seoul St. Mary Hospital. These institutions manage commercial products like Kymriah for lymphoma and leukemia patients.

• Samsung Medical Center: Established the first dedicated CAR T-Cell Center in South Korea in 2021.
• Seoul National University: First hospital authorized to produce CAR T-cells internally for pediatric leukemia cases.
• Seoul St. Mary: Features an on-site GMP cell processing center for advanced immune cell research.
• Regulatory compliance: Facilities must strictly follow the Advanced Biological Product Safety Act for certification.

Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and maintains a presidential-tier infrastructure. This high volume translates to significant experience in complex oncology. Their early adoption of a dedicated center makes them a leader in managing cytokine release syndrome. This specialized care is vital for patient safety during the aggressive CAR T-cell infusion phase.

Patient Consensus: Patients emphasize the need for official verification. They recommend contacting oncology departments directly to confirm current KFDA approval status for specific therapies. Many suggest budgeting over $300,000 and planning for a 6-week stay.

South Korea's Ministry of Food and Drug Safety has approved four major CAR T-cell therapies: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Carvykti (ciltacabtagene autoleucel), and Rimqarto (anbalcabtagene autoleucel). These products treat specific lymphomas and multiple myeloma. Administration occurs at specialized centers like Samsung Medical Center.

• Kymriah (Novartis): Approved in 2021 for pediatric ALL and adult DLBCL.
• Yescarta (Gilead): Treats relapsed large B-cell lymphoma and primary mediastinal lymphoma.
• Carvykti (Janssen): Indicated for adult patients with relapsed or refractory multiple myeloma.
• Rimqarto (Curocell): The first homegrown Korean CAR T-cell drug targeting CD19.

Bookimed Expert Insight: While approvals are increasing, manufacturing logistics remain a significant bottleneck. Data shows patients often wait over 6 months for imported products. Top centers like Samsung Medical Center manage these timelines better due to high patient volumes. They serve over 2,000,000 patients annually and have established apheresis protocols.

Patient Consensus: Patients emphasize the need to verify hospital capabilities early. They often report that insurance coverage lags behind regulatory approval, making out-of-pocket costs a major concern.

South Korea National Health Insurance covers CAR T-cell therapy primarily for relapsed or refractory diffuse large B-cell lymphoma and pediatric B-cell acute lymphoblastic leukemia. Coverage usually applies starting from third-line treatment under strict National Health Insurance Service guidelines at accredited medical centers.

• Large B-cell lymphoma: Reimbursed as third-line therapy for adult patients with relapsed or refractory disease.
• Acute lymphoblastic leukemia: Covered for pediatric and young adult patients up to 25 years old.
• Mantle cell lymphoma: Benefits expanded in 2022 to include this specific hematologic malignancy.
• Follicular lymphoma: Approved for clinical use but reimbursement varies significantly by individual case.

Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and holds KOIHA accreditation for safety. Their high volume suggests they manage the complex National Health Insurance reimbursement and hospital-level approvals efficiently. Patients should verify their specific malignancy against the latest risk-sharing agreements at such high-capacity centers.

Patient Consensus: Patients report that while pediatric leukemia coverage is reliable, many adults with multiple myeloma face private costs. Most advise preparing for a 10% to 20% copay even when insurance approves the treatment.

South Korea actively recruits for CAR T-cell clinical trials targeting lymphoma, leukemia, and liver cancer. Prominent studies include the ALPHA3 trial for B-cell lymphoma and the EU307 phase 1 trial for hepatocellular carcinoma. Enrollment centers include Samsung Medical Center and Seoul National University Hospital.

• Hematologic malignancies: The ALPHA3 trial evaluates first-line consolidation for large B-cell lymphoma.
• Leukemia research: Anbal-cel phase 2 trials investigate treatments for adult acute lymphoblastic leukemia.
• Solid tumors: EU307 phase 1 tests anti-GPC3 therapy for advanced liver cancer patients.
• Autoimmune applications: Clinics recruit for low-dose CAR-T trials treating refractory Systemic Lupus Erythematosus.

Bookimed Expert Insight: While many global trials use ClinicalTrials.gov, South Korean centers often prioritize the local CRIS registry. Samsung Medical Center, which serves over 2,000,000 patients annually, frequently operates internal trial pipelines. Checking their specific Cancer Center listings usually reveals more active slots than international databases.

Patient Consensus: Many find that trial information is mainly available in Korean. Direct contact with tier-1 hospital international departments is more effective than searching public online listings.